Davita Calls Whistleblowers' FCA Kidney Drugs Suit Flawed - McDermott Will & Emery

Davita Calls Whistleblowers’ FCA Kidney Drugs Suit Flawed

Overview


McDermott was mentioned as one of four law firms representing a leading dialysis provider in ongoing Fair Claims Act litigation. The latest filing on the company’s behalf in Georgia federal court sought to dismiss the suit, saying that its dosing practices were objectively reasonable and cannot be used to hold it liable under the FCA.